Hepatitis b reactivation and rituximab in the oncology practice

Oncologist

Volumn 15, Issue 10, 2010, Pages 1113-1121

  Villadolid, Jeryl ^a   la Plant, Kourtney D ^a   Markham, Merry Jennifer ^b   Nelson, David R ^c   George Jr , Thomas J ^b  

^a Department of Pharmacotherapy and Translational Research   (United States)

^b Division of Hematology/Oncology   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BENDAMUSTINE; BLEOMYCIN; CARMUSTINE; CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HYDROCORTISONE; IFOSFAMIDE; LAMIVUDINE; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; THIOTEPA; VINBLASTINE; VINCRISTINE; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; B CELL DEPLETION; CANCER COMBINATION CHEMOTHERAPY; CHILL; CLINICAL TRIAL; DECOMPENSATED LIVER CIRRHOSIS; DRUG EXCRETION; DRUG FATALITY; DRUG FEVER; DRUG METABOLISM; DRUG TOLERABILITY; GRAFT VERSUS HOST REACTION; HEPATIC FLARE; HEPATITIS B; HEPATITIS B VIRUS; HEPATOMEGALY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; INFECTION RISK; LACTIC ACIDOSIS; LARGE CELL LYMPHOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; LIVER METABOLISM; LIVER NECROSIS; LYMPHOCYTE DEPLETION; LYMPHOCYTOPENIA; MORTALITY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PANCREATITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROPHYLAXIS; RHEUMATOID ARTHRITIS; RISK FACTOR; RISK REDUCTION; SEROLOGY; SIDE EFFECT; STEATOSIS; TREATMENT DURATION; TUMOR LYSIS SYNDROME; VIRUS LOAD; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MALE; NEOPLASMS; RISK FACTORS; VIRUS ACTIVATION;

EID: 77958588509     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0106     Document Type: Article

References (70)

1. Coiffier B, Feugier P, Mounier N et al. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients. J Clin Oncol 2007;25(suppl 18S):443s. Abstract 8009.
2. Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127.
3. Pfreundschuh M, Trümper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7(5):379-391.
4. Marcus R, Imrie K, Catalano J et al. Rituximab plus CVP improves survival in previously untreated patients with advanced follicular non-Hodgkin's lymphoma. Paper presented at: American Society of Hematology 48th Annual Meeting and Exposition; December 9-12, 2006; Orlando, FL; Abstract 481.
5. Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135-3143.
6. McLaughlin P, GrilloLopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833.
7. Piro LD, White CA, Grillo-Lopez AJ et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999;10:655-661.
8. Davis TA, White CA, Grillo-Lopez AJ et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999;17(6):1851-1857.
9. Hochster HS, Weller E, Ryan T et al. Results of E1496: a phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). J Clin Oncol 2004;22(suppl):Abstract 6502.
10. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54(9):2793-2806.
11. Rituximab Package Insert. South San Francisco, CA: Biogen Idec, Inc. and Genentech, Inc., 2007.
12. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-220.
13. Coiffier B. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of lamivudine prophylaxis. Cancer Invest 2006;24:548-552.
14. Loomba R, Rowley A, Wesley R et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-528.
15. Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006;24:1003-1016.
16. Rossi G. Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato- oncological neoplasias treated with chemotherapy. Leuk Lymphoma 2003;44:759-766.
17. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
18. Keeffe EB, Dieterich DT, Han ShB et al. Clin Gastroenterol Hepatol 2008; 6:1315-1341.
19. Artz AS, Somerfiled MR, Feld JJ et al. American Society of Clinical Oncology Provisional Clinical Opinion: Chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant disease. J Clin Oncol. 2010 Jun 1 [Epub ahead of Print].
20. Vega J, Khalife M, Hanbali A et al. Incidence of liver events in patients with hepatitis B and C treated with rituximab. J Clin Oncol 2008;26(suppl): Abstract 8558.
21. Yeo W, Chan TC, Leung NWY et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605-611.
22. World Health Organization. Rituximab: possible association with hepatitis B reactivation. WHO Pharm Newsletter 2004(5):5.
23. Hui CK, Cheung WW, Zhang HY et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006;131:59-68.
24. Hanbali A, Khaled Y. Incidence of hepatitis B reactivation following rituximab therapy. Am J Hematol 2009;84(3):195.
25. Koo YX, Tan DSW, Tan BH et al. Correspondence: Risk of hepatitis B virus reactivation in patients who are hepatitis B surface antigen negative/antibody to hepatitis B core antigen positive and the role of routine antiviral prophylaxis. J Clin Oncol 2009;27:2570-2571.
26. Metzler F, Mederacke I, Manns MP et al. Rituximab leads to reactivation of hepatitis B in individuals with resolved infection. Hepatology 2008;48: 685A. AASLD Abstract 848.
27. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
28. Zelenetz AD, Abramson JS, Advani RH et al. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas. J Natl Compr Canc Netw 2010;8:288-334.
29. Lexi-Comp. Lexi-Comp Online. Available at http://www.lexicomponline.com. Accessed December 18, 2009.
30. DCTD, NCI, NIH, DHHS. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0. Publish Date August 9, 2006. Available at http://ctep.cancer.gov.
31. Lok AS, Lai CL, Wu PC et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987;92(6):1839-1843.
32. Lok AS, Lai CL. alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989;9:110.
33. Silvestri F, Ermacora A, Sperotto A et al. Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol 2000;108:394-396.
34. Arzerra ® Package Insert. Research Triangle Park, NC: GlaxoSmithKline. Available at: http://us.gsk.com/products/assets/us_arzerra.pdf. Accessed January 24, 2009.
35. Dore GJ, Cooper DA, Barrett C. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus coinfected persons in a randomized, controlled study (CAESAR). J Infect Dis 1999;180(3):607-613.
36. DeJesus E, McCarty D, Farthing CF et al. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treat-ment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis 2004;39(3):411-418.
37. Cre ́mieux AC et al. A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus lamivudine-zidovudine double combination tablet by HIV-1 infected adults. Pharmacotherapy 2001;21(4):424-430.
38. McKinney RE Jr, Johnson GM, Stanley K et al. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. J Pediatr 1998;133(4):500-508.
39. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341(17):1256-1263.
40. Lai CL, Chien RN, Leung NWY et al. A one-year trial of lamivudine for chronic hepatitis B. New Engl J Med 1998;339:61-68.
41. Schiff ER, Dienstag JL, Karayalcin S et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003;38(6): 818-826.
42. Jonas MM, Kelley DA, Mizerski J et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-1713.
43. Jang JW, Choi JY, Bae SH et al. A randomized controlled study preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006;43:233-240.
44. Lau GK, Yiu HH, Fong DY et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-1749.
45. Cardinale G, Merenda A, Pagliaro M et al. Possible efficacy of lamivudine prophylaxis to prevent hepatitis B virus reactivation due to rituximab regimens in hepatitis B virus carriers with B cell lymphoprolipherative malignancies. Haematologica 2008;93:S103.
46. Dai MS, Wu PF, Lu JJ et al. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study. Support Care Cancer 2004;12:191-196.
47. Dai MS, Wu PF, Shyu RY et al. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 2004;24:540-546.
48. el-Sayed MH, Shanab G, Karim AM et al. Lamivudine facilitates optimal chemotherapy in hepatitis B virus infected children with hematological malignancies: a preliminary report. Pediatr Hematol Oncol 2004;21:145-156.
49. He Y-F, Li Y-H, Wang F-H et al. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann Hematol 2008;87:481-485.
50. Hsu C, Sur IJ, Hwang WS et al. A prospective comparative study of prophylactic or therapeutic use of lamivudine for chemotherapy-associated hepatitis B (HBV) reactivation in non-Hodgkin's lymphoma patients. Gastroenterology 2006;131:S297.
51. Hui CK, Cheung WW, Au WY et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic hemotherapy. Gut 2005;54:1597-1603.
52. Idilman R, Arat M, Soydan E et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 2004;11:141-147.
53. Jia J, Lin F. Lamivudine therapy for prevention of chemotherapy-induced reactivation of hepatitis B virus. Zhonghua Gan Zang Bing Za Zhi 2004; 12:628-629.
54. Rossi G, Pelizzari A, Motta M et al. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001;115:58-62.
55. Shibolet O, Ilan Y, Gillis S et al. Lamivudine therapy for prevention of immunosuppressive- induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002;100:391-396.
56. Vassiliadis T, Garipidou V, Tziomalos K et al. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with hemotherapy - a prospective case series. Am J Hematol 2005;80:197-203.
57. Yeo W, Chan PK, Ho WM et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927-934.
58. Yeo W, Ho WM, Hui P et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004;88:209-215.
59. Yeo W, Hui EP, Chan AT et al. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. AmJ Clin Oncol 2005;28:379-384.
60. Leaw SJ, Yen CJ, Huang WT et al. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004;83:270-275.
61. Lee GW, Ryu MH, Lee JL et al. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBsAg) positive patients with non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci 2003;18:849-854.
62. Lim LL, Wai CT, Lee YM et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 2002;16:1939-1944.
63. Nagamatsu H, Itano S, Nagaoka S et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HB e antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol 2004;99:2369-2375.
64. Ozguroglu M, Bilici A, Turna H et al. Reactivation of hepatitis B infection with cytotoxic therapy in non-Hodgkin's lymphoma. Med Oncol 2004;21: 67-72.
65. Persico M, De Marino F, Russo GD et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002;99:724-725.
66. Yokoyama M, Ennishi D, Takeuchi K et al. Lamivudine prophylaxis is effective for inhibition of hepatitis B viral reactivation in patients with diffuse large b-cell lymphoma undergoing R-CHOP like therapy. Ann Oncol 2008; 19(suppl 4):141. ICML Abstract 140.
67. Lamivudine Package Insert. Research Triangle Park, NC: GlaxoSmith-Kline, 2004.
68. Ziakas P, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a metaanalysis of published clinical trials and a decision tree addressing prolong prophylaxis and maintenance. Haematologica 2009;94:998-1004.
69. Simpson ND, Simpson PW, Ahmed AM et al. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with lamivudine. J Clin Gastroenterol 2003;37:68-71.
70. Sandherr M, Einsele H, Hebart H et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 2006;17:1051-1059.